Advertisement


Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Opening Session Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Advertisement